Clearmind Medicine annual r&d spending
2021
2022
2023
2024
2025
Clearmind Medicine R&D Spending Growth & History (CMND)
Clearmind Medicine's r&d spending was $2.1M for fiscal 2025.
View full Clearmind Medicine company overviewClearmind Medicine annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-10-31 | $2.1M | $673,717 | +48.72% |
| 2024 | 2024-10-31 | $1.4M | −$161,421 | −10.45% |
| 2023 | 2023-10-31 | $1.5M | −$1.5M | −49.88% |
| 2022 | 2022-10-31 | $3.1M | $2.6M | +550.48% |
| 2021 | 2021-10-31 | $473,652 | — | — |
Clearmind Medicine quarterly r&d spending
Q2.22
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-04-30 | $646,707 | $194,850 | +43.12% |
| Q1 2026 | 2026-01-31 | $640,494 | $179,056 | +38.80% |
| Q4 2025 | 2025-10-31 | $420,182 | −$281,041 | −40.08% |
| Q3 2025 | 2025-07-31 | $723,048 | $377,165 | +109.04% |
| Q2 2025 | 2025-04-30 | $451,857 | $128,901 | +39.91% |
| Q1 2025 | 2025-01-31 | $461,438 | $448,692 | +3520.26% |
| Q4 2024 | 2024-10-31 | $701,223 | — | — |
| Q3 2024 | 2024-07-31 | $345,883 | $81,929 | +31.04% |
| Q2 2024 | 2024-04-30 | $322,956 | $5,384 | +1.70% |
| Q1 2024 | 2024-01-31 | $12,746 | — | — |
| Q3 2023 | 2023-07-31 | $263,954 | — | — |
| Q2 2023 | 2023-04-30 | $317,572 | −$843,186 | −72.64% |
| Q2 2022 | 2022-04-30 | $1.2M | — | — |
Clearmind Medicine r&d spending trends
Between the periods ended 2021-10-31 and 2025-10-31, Clearmind Medicine's r&d spending increased from $473,652 to $2.1M, a change of $1.6M. The latest reported quarter, Q2 2026, shows $646,707.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Clearmind Medicine source filings ↗